What Is Goserelin? Definition and What Research Reports
Goserelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH), formulated as a long-acting subcutaneous depot implant. By continuously stimulating pituitary GnRH receptors, it downregulates them and suppresses sex-hormone production. Published research has studied goserelin as a comparator and combination agent in prostate cancer, hormone receptor-positive breast cancer and adenomyosis, and as a model molecule in sustained-release formulation work. Case reports have described local injection-site and imaging-related findings.
Definition
Goserelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH, also called luteinising hormone-releasing hormone or LHRH). It belongs to the class of GnRH receptor agonists: rather than blocking the receptor, it binds and activates it. Because the natural hormone is released in pulses, continuous exposure to a long-acting agonist first causes a transient surge in luteinising hormone and follicle-stimulating hormone, then downregulates and desensitises pituitary GnRH receptors, which lowers circulating testosterone in males and oestradiol in females. Goserelin is most familiar in clinical literature as goserelin acetate, delivered as a biodegradable polymer depot implanted subcutaneously so that a single administration releases peptide over weeks. It is a laboratory-made molecule — not extracted from tissue — and its structure is a modified version of the ten-amino-acid human GnRH sequence, altered so that it resists rapid enzymatic breakdown.
This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or medication.
Molecular Class and Origin
- Class: peptide hormone analogue; GnRH/LHRH receptor agonist.
- Size: decapeptide (ten amino acid residues), typically handled as the acetate salt.
- Origin: chemically synthesised; a structural analogue of endogenous human GnRH, not a naturally occurring peptide.
- Typical formulation in the literature: a depot implant or microsphere system designed for sustained release rather than daily administration.
- Mechanistic label: often grouped with other GnRH agonists such as leuprolide and triptorelin in comparative analyses (cost-effectiveness analysis of triptorelin, goserelin and leuprolide in metastatic prostate cancer).
How the Term Is Used in Peptide Research
In peptide science, "goserelin" appears in three broad contexts. First, as an endocrine agent in oncology and gynaecology trials, where hormone suppression is the intended pharmacology. Second, as a reference comparator when newer GnRH-directed products are tested for non-inferiority. Third — and this is where it shows up most often in formulation and drug-delivery journals — as a model peptide for sustained-release engineering, because its small size, water solubility and need for multi-week dosing make it a demanding test case for depot systems.
That third use is well represented. Researchers prepared and evaluated uniform-sized goserelin-loaded sustained-release microspheres, reporting in vitro and in vivo characterisation of the release system in a 2024 controlled-release study. A separate group described a rapidly dissolving microneedle patch embedded with long-acting microspheres intended to give sustained goserelin release, reported in 2025 in the Journal of Controlled Release. Analytical-method work has also used the peptide as a target analyte: a study developed and validated an LC-MS/MS method to quantify goserelin in a Pheroid formulation in simulated intestinal fluid published in 2020. Preclinically, pharmacological and toxicological studies of a novel goserelin acetate extended-release microsphere formulation were carried out in rats and reported in 2023.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
The clinical literature cited here spans oncology, gynaecology and health economics. In prostate cancer, a multicentre, randomised, open-label phase III non-inferiority trial compared LY01005 with a goserelin implant in Chinese patients and reported on efficacy and safety of the two arms. In breast cancer, a real-world cohort study compared goserelin 10.8 mg with goserelin 3.6 mg in premenopausal and perimenopausal Chinese patients with hormone receptor-positive disease and examined effectiveness across the two depot strengths.
Beyond those two settings, a phase II trial (DISCOVARY) evaluated darolutamide alone and in combination with goserelin in androgen receptor-positive salivary gland carcinoma with results reported in the Journal of Clinical Oncology. In benign gynaecology, a prospective cohort study assessed efficacy and uterine bleeding patterns when goserelin therapy was initiated during different menstrual phases in patients with adenomyosis and reported bleeding-pattern differences by initiation timing. From a systems perspective, researchers modelled the cost-effectiveness of triptorelin, goserelin and leuprolide in metastatic prostate cancer from a societal viewpoint in a 2024 analysis.
Research Contexts at a Glance
| Context | What was studied | Citation |
|---|---|---|
| Prostate cancer | Goserelin implant as active comparator in a phase III non-inferiority trial | PMID 37010251 |
| Breast cancer | Real-world comparison of 10.8-mg and 3.6-mg depot strengths (reported 2025) | PMID 40814439 |
| Salivary gland carcinoma | Combination with darolutamide in AR-positive disease | PMID 42546251 |
| Adenomyosis | Initiation during different menstrual phases; bleeding patterns | PMID 39373327 |
| Drug delivery | Microspheres, microneedle patches, LC-MS/MS quantification | PMID 39349185 |
| Health economics | Cost-effectiveness versus other GnRH agonists | PMID 38663058 |
Administration Route in the Literature
Because goserelin is supplied as a solid implant rather than a solution, the injection procedure itself has been a subject of published nursing research. One report examined administration of goserelin at alternative injection sites in premenopausal breast cancer and discussed site selection in that population. Formulation researchers have pursued alternatives to the standard implant for the same reason — the microneedle-patch work described sustained release from a rapidly dissolving patch as a delivery route distinct from a large-bore implant needle in the 2025 report. Nothing here describes how any product is administered in practice; these are summaries of what was published.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events and Incidental Findings: What Studies Report
Safety data appear both in controlled trials and in single-patient case reports. The phase III non-inferiority trial in Chinese patients with prostate cancer assessed safety alongside efficacy for the goserelin implant arm as reported in 2023. Case-level literature adds two distinct signals. A case report described a goserelin-induced chemical burn, accompanied by a review of similar published cases in Cureus in 2023. Separately, a case report described goserelin inhibiting uptake on a sodium pertechnetate Tc-99m thyroid scan, an imaging interaction relevant to interpreting nuclear medicine studies and published in 2024. Preclinical safety characterisation of an extended-release microsphere version was reported in toxicological studies in rats in 2023. Case reports describe single individuals and do not establish how often an event occurs.
Related Terms
- GnRH / LHRH: the endogenous hypothalamic decapeptide that goserelin mimics.
- GnRH agonist: the class containing goserelin, leuprolide and triptorelin (compared in a 2024 cost-effectiveness analysis).
- Depot implant: a solid sustained-release dosage form placed subcutaneously.
- Androgen deprivation: the pharmacological goal in prostate cancer studies using GnRH agonists.
- Ovarian function suppression: the corresponding goal in premenopausal breast cancer research (examined in a 2025 cohort study).
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeScope and Limits of This Entry
This is a definitional reference entry. It does not summarise every goserelin trial, does not weigh benefits against risks, and does not describe regimens. Goserelin is a prescription pharmaceutical in the jurisdictions where it is marketed; decisions about any hormone-suppressing agent belong to a treating clinician who can evaluate an individual case. Where this page states an effect, a comparison or an adverse event, the sentence links to the specific publication that reported it, and readers can follow those links to read the primary abstracts.
References
- Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial (Chinese Medical Journal, 2023)
- Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a cohort study (Journal of the National Cancer Center, 2025)
- Cost-Effectiveness Analysis of Triptorelin, Goserelin, and Leuprolide in the Treatment of Patients With Metastatic Prostate Cancer: A Societal Perspective (Value in Health Regional Issues, 2024)
- Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin (Journal of Controlled Release, 2025)
- Goserelin inhibiting uptake on sodium pertechnetate Tc-99m thyroid scan: a case report (Annals of Ibadan Postgraduate Medicine, 2024)
- Development and validation of an LC-MS/MS method for the quantification of goserelin in a Pheroid formulation, in simulated intestinal fluid (Journal of Pharmaceutical and Biomedical Analysis, 2020)
- Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature (Cureus, 2023)
- Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial (Journal of Clinical Oncology, 2026)
- Administration of Goserelin at Alternative Injection Sites for Premenopausal Breast Cancer (Clinical Journal of Oncology Nursing, 2024)
- Efficacy and uterine bleeding patterns in initiating goserelin therapy during different menstrual phases in patients with adenomyosis: a prospective cohort study (Gynecological Endocrinology, 2024)
- Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats (Frontiers in Pharmacology, 2023)
- Preparation and in vitro/in vivo evaluation of uniform-sized Goserelin-loaded sustained release microspheres (Journal of Controlled Release, 2024)
Frequently asked questions
Is goserelin a peptide?▾
Yes. Goserelin is a synthetic decapeptide — ten amino acid residues — built as a structural analogue of human gonadotropin-releasing hormone. It is chemically synthesised rather than extracted from tissue, and is usually handled as goserelin acetate. Formulation researchers have treated it as a model peptide for depot systems, including uniform-sized sustained-release microspheres (PMID 39349185).
What class of molecule does goserelin belong to?▾
Goserelin is classed as a GnRH (LHRH) receptor agonist. Continuous receptor activation downregulates pituitary GnRH receptors and lowers sex-hormone output. Health-economic literature groups it with other agonists in the same class: a 2024 societal-perspective analysis compared triptorelin, goserelin and leuprolide in metastatic prostate cancer (PMID 38663058).
In what research settings does goserelin appear?▾
Published work spans oncology, gynaecology and drug delivery. A phase III non-inferiority trial used a goserelin implant as the comparator in Chinese patients with prostate cancer (PMID 37010251), a cohort study compared depot strengths in hormone receptor-positive breast cancer (PMID 40814439), and a prospective cohort examined therapy initiation across menstrual phases in adenomyosis (PMID 39373327).
How is goserelin usually formulated in studies?▾
Most published clinical work used a long-acting subcutaneous depot implant rather than a daily injection. Researchers have also developed alternatives: uniform-sized sustained-release microspheres were prepared and evaluated in vitro and in vivo (PMID 39349185), and a rapidly dissolving microneedle patch embedded with long-acting microspheres was reported for sustained release (PMID 41213385).
What adverse events have studies reported with goserelin?▾
Safety was assessed alongside efficacy in the phase III prostate cancer non-inferiority trial (PMID 37010251). Case-level reports add specific findings: one described a goserelin-induced chemical burn with a review of similar published cases (PMID 37745751), and another described goserelin inhibiting uptake on a sodium pertechnetate Tc-99m thyroid scan (PMID 38939893). Case reports describe single patients only.
Has goserelin been studied in combination with other drugs?▾
Yes. The phase II DISCOVARY trial evaluated darolutamide alone and in combination with goserelin in androgen receptor-positive salivary gland carcinoma, with results reported in the Journal of Clinical Oncology (PMID 42546251). This page does not compare regimens or outcomes; treatment decisions belong to a licensed physician.
Is goserelin available as a research chemical?▾
Goserelin is a prescription pharmaceutical in the jurisdictions where it is marketed, and published human studies were conducted in clinical trial settings. Laboratory literature uses it as an analytical and formulation target — for example, an LC-MS/MS method was developed and validated to quantify goserelin in a Pheroid formulation in simulated intestinal fluid (PMID 31865209). This entry is definitional and not medical advice.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.